Portfolio 10
| Date | Name | Website | Total Raised | Location |
| 10.10.2016 | OncoRespon... | oncoresponseinc.com | $153.1M | United Sta... |
| - | MEI Pharma | meipharma.com | $102.5M | United Sta... |
| - | Amal Thera... | amaltherapeutics.com | $90.9M | Switzerlan... |
| - | On Target ... | ontargetlaboratories.com | $21M | - |
| - | Aadi Biosc... | aadibio.com | $95.5M | United Sta... |
| - | QuantuMDx | quantumdx.com | $2.65M | United Kin... |
| - | Greenbone | greenbone.it | $24.64M | Italy, Emi... |
| - | Gain Thera... | gaintherapeutics.com | $58.84M | United Sta... |
| - | Personal G... | personalgenome.com | $202.2M | United Sta... |
| - | NovellusDx | novellusdx.com | $6M | - |
News 22
Show more
Mentions in press and media 17
| Date | Title | Description |
| 31.01.2020 | Lyfebulb and Helsinn Announce the Winners of the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award | MONACO, PRINCIPALITY OF MONACO, AND NEW YORK, NY, USA, January 31, 2020: Lyfebulb, a patient empowerment platform that connects patients with industry to support user-driven innovation toward solutions in chronic disease, and Helsinn, a Swi... |
| 15.07.2019 | Helsinn Investment Fund Announces First Exit | Luxembourg, 15 July 2019 Helsinn Investment Fund S.A, SICAR, a fund focused on early-stage investment opportunities in areas of high unmet patient need, today announces the fund first exit since launching in 2016. |
| 19.03.2019 | Winners of the Second Annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology Announced | MONACO, PRINCIPALITY OF MONACO and NEW YORK, NY, MARCH 19, 2019: |
| 19.02.2019 | Helsinn Investment Fund Invests €1 Million in Gain Therapeutics | Luxembourg, 19 February 2019: Helsinn Investment Fund S.A, SICAR, a fund focused on early-stage investment opportunities in areas of high unmet patient need, today announces that it has made a €1 Million investment in Gain Therapeutics SA... |
| 12.11.2018 | AMAL Therapeutics finalises CHF 33 million Series B round | |
| 30.04.2018 | NovellusDx Announces It Has Completed an Equity Financing of $6 Million | Jerusalem, Israel, 30 April 2018 – NovellusDx, the leader in functional genomics, today announced it has completed an equity financing of $6 million. The financing round is with the participation of Helsinn Investment Fund S.A. SICAR, par... |
| 28.03.2018 | Winners of the Inaugural Lyfebulb-Helsinn Innovation Summit & Awards in Oncology Announced | Lorenzo Pradella of GreenBone Ortho, srl has been selected from eleven finalists as the winner of the first-ever Lyfebulb-Helsinn Innovation Award in Oncology. |
| 14.03.2018 | On Target Laboratories Raises Additional Capital from H.I.G. BioHealth Partners, Elevate Ventures and Helsinn | WEST LAFAYETTE, Ind. 14 March 2018 – On Target Laboratories, Inc., a privately-held biotechnology company that is developing tumour-targeted fluorescent dyes to improve cancer surgery, has secured additional financing as part of its Serie... |
| 05.09.2017 | AMAL Therapeutics Raises €8 Million (CHF 8.8 Million) in First Closing of Series B Financing Round | Financing round co-led by Boehringer Ingelheim Venture Fund, BioMedPartners and Helsinn Investment Fund |
| 16.06.2017 | Helsinn Investment Fund Leads the Financial Round in GreenBone | Lugano, Switzerland, 16 June 2017: Helsinn Investment Fund S.A., a fund focused on early-stage investments in areas of high unmet patient need, today announces that it has made a Euro 2M investment in GreenBone, a privately-held developer o... |
Show more